BriaCell Therapeutics Corp. (BCTX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$29.9M
Cash & Equivalents
$15.7M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$34M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06471673 A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer PHASE2 Recruiting 18

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BCTX.

SEC EDGAR Filings

All SEC filings for BriaCell Therapeutics Corp. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.